Characteristics of the study group
| Feature . | No. (% of 28 patients) . |
|---|---|
| Age, y | |
| Median | 43 |
| 50 or older | 8 (29) |
| Splenomegaly | 5 (18) |
| Anemia, hemoglobin level less than 10 g/dL | 12 (43) |
| Platelet counts, × 109/L | |
| Lower than 100 | 12 (43) |
| Higher than 450 | 2 (7) |
| Cytogenetic clonal evolution | 20 (71) |
| Preparative regimen before transplantation | |
| Total body irradiation | 13 (46) |
| No total body irradiation | 13 (46) |
| Unknown | 2 (7) |
| Donor source | |
| Related | 17 (61) |
| Urelated | 11 (39) |
| Stem cell source | |
| Marrow | 25 (89) |
| Blood | 3 (11) |
| Time after allogeneic SCT to relapse, mo | |
| Less than 12 | 17 (61) |
| 12-24 | 5 (18) |
| More than 24 | 6 (21) |
| Salvage therapy after relapse | |
| DLI | 13 (46) |
| IFN-α | 9 (32) |
| Other | 6 (21) |
| Disease status at imatinib mesylate therapy | |
| Chronic phase, CHR but PCR-positive | 1 (4) |
| Chronic phase, active | 4 (14) |
| Accelerated phase | 15 (54) |
| Blastic phase | 8 (29) |
| Feature . | No. (% of 28 patients) . |
|---|---|
| Age, y | |
| Median | 43 |
| 50 or older | 8 (29) |
| Splenomegaly | 5 (18) |
| Anemia, hemoglobin level less than 10 g/dL | 12 (43) |
| Platelet counts, × 109/L | |
| Lower than 100 | 12 (43) |
| Higher than 450 | 2 (7) |
| Cytogenetic clonal evolution | 20 (71) |
| Preparative regimen before transplantation | |
| Total body irradiation | 13 (46) |
| No total body irradiation | 13 (46) |
| Unknown | 2 (7) |
| Donor source | |
| Related | 17 (61) |
| Urelated | 11 (39) |
| Stem cell source | |
| Marrow | 25 (89) |
| Blood | 3 (11) |
| Time after allogeneic SCT to relapse, mo | |
| Less than 12 | 17 (61) |
| 12-24 | 5 (18) |
| More than 24 | 6 (21) |
| Salvage therapy after relapse | |
| DLI | 13 (46) |
| IFN-α | 9 (32) |
| Other | 6 (21) |
| Disease status at imatinib mesylate therapy | |
| Chronic phase, CHR but PCR-positive | 1 (4) |
| Chronic phase, active | 4 (14) |
| Accelerated phase | 15 (54) |
| Blastic phase | 8 (29) |